AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining forces with Aptar to develop algorithms that can be used to detect CKD ...

President Donald Trump is rumoured to be resurrecting a policy proposed in his first term that would see drug prices offered to federal programmes tied to those offered overseas. According to ...

Despite significant R&D investments, pharma companies often underestimate the multifaceted challenges of bringing promising treatments to market – from securing favourable reimbursement to ...

In March, the UK marked Prostate Cancer Awareness Month - a period dedicated to boosting recognition and tackling stigma of a cancer that affects approximately one in eight men nationwide.

In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Meanwhile at SpinCo, a new spinoff of Galapagos, Henry Gosebruch was appointed CEO. Gosebruch was previously president and ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

Shares in the digital therapeutics (DTx) developer closed up more than 17% after its debut on the NYSE at $32 under the HNGE ...